Phase 1 and 2 studies with NOX-E36 have shown its ability to target macrophages in a dose-dependent manner and have established its safety and tolerability profile in over 100 subjects. NOXXON plans to put NOX-E36 back into the clinic in 2021 as part of its clinical development plan to treat solid tumors such as pancreatic and liver cancer.

Mechanism of Action
NOX-E36 (emapticap pegol) binds and neutralizes the human chemokine CCL2* as well as some highly related chemokines. Chemokines can be thought of as road signs in the body that can direct movement of cells that encounter them. Like road signs, chemokines are anchored in place (location information) and contain directions, such as “enter here”, for cells that can “see” them with the appropriate receptors. CCL2 is one of the key chemokines that regulate migration and infiltration of key components of the innate immune system called monocytes/macrophages. Both CCL2 and its receptor CCR2 are implicated in cancer spread and immune privilege of tumors and have been demonstrated to be involved in a variety of inflammatory diseases. One key function of CCL2 is the recruitment of immunosuppressive cell populations of the innate immune system such as Tumor Associated Macrophages (TAMs). Removing TAMs from the tumor microenvironment with NOX-E36 should allow an improved immune response against tumors.

*CCL2 (C-C Chemokine Ligand 2) is also referred to as MCP-1 (Monocyte Chemoattractant Protein 1)

Recent clinical studies available at clinicaltrials.gov

  • NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
    (ref: NCT01547897)
    Status: completed

Recent NOX-E36 press releases


NOX-E36 press release archive

NOX-E36 publication archive